Crestovo was launched to advance the years of foundational clinical research and development of the company’s founder and scientific advisor Dr. Thomas J. Borody, and academic collaborators, Dr. Alexander Khoruts and Dr. Michael Sadowsky. Their collective work has validated orally-administered, full-spectrum bacterial composition products across a variety of serious diseases and medical needs, including recurrent Clostridium difficile infection (CDI, also commonly referred to as C. difficile or C. diff).
We are leveraging our novel, industry-leading Full-Spectrum Microbiota™ (FSM™) platform to develop a clinical pipeline of orally-administered products to treat a range of serious diseases, including recurrent CDI. Our lead FSM™ product candidate, CP101, is currently in a clinical trial called PRISM 3, with top-line data expected in 2018.
Chief Operating Officer and Interim Chief Executive Officer
Joseph Lobacki is Crestovo’s chief operating officer and interim chief executive officer. Prior to Crestovo, Mr. Lobacki was chief commercial officer at Medivation, which was acquired by Pfizer in September 2016. Previously, Mr. Lobacki served as the general manager of the oncology business at Idera Pharmaceuticals, senior vice president and chief commercial officer at Micromet Inc., senior vice president and general manager of transplant and oncology at Genzyme Corporation, vice president of North American marketing at SangStat Medical Corporation and vice president of operations of Cell Pathways, Inc.
Mr. Lobacki holds a B.S. in biology from Boston College and a B.S. in pharmacy from Massachusetts College of Pharmacy.
Kirk Taylor, M.D.
Chief Medical Officer
Kirk Taylor is Crestovo’s chief medical officer. Dr. Taylor brings more than 20 years of pharmaceutical and biotech industry experience across a range of therapeutic areas and 12 years in clinical practice to the company. Prior to Crestovo, he served as chief medical officer of Prescient Medicine and chief executive officer of New-Starts Consulting, an independent clinical development consultancy for biotech and pharmaceutical companies. Dr. Taylor previously held executive leadership positions at Pfizer, Actelion, Biogen, Alzheon, Inc. and Sanofi-Genzyme focusing in late-stage clinical development, laboratory medicine and medical affairs, and played key roles in product launches including, RELPAX®, MACUGEN®, LYRICA®, TECFIDERA®, ALPROLIX®, and ELOCTATE®. Prior to joining the industry, Dr. Taylor was a faculty member in the neurology department at the University of California, San Francisco.
Dr. Taylor holds a B.A. from Harvard University and an M.D. from SUNY Downstate Medical Center. He has completed Executive M.B.A. leadership programs at Harvard Business School and INSEAD. He currently serves as a member of the Massachusetts Board of Directors for Bottom Line, a non-profit organization focused on increasing graduation rates among low-income and first-generation college students.
Bharat Dixit, Ph.D.
Vice President, Bioprocess Development and Manufacturing
Bharat Dixit leads all production, method development and quality assurance efforts for Crestovo. Dr. Dixit has more than 11 years of experience in the biopharmaceutical industry, developing complex biologics. Most recently, Dr. Dixit led the analytical and formulation development group at Genocea Biosciences, where he was involved in the development of HSV-2 and Streptococcus pneumoniae vaccines. Prior to Genocea, Dr. Dixit held positions at Formatech, Inc. and Sanofi Pasteur.
Dr. Dixit completed his post-doctoral research at the University of Massachusetts Medical School, Worcester and University of Texas Medical Branch at Galveston, and earned his Ph.D. in biochemistry from the Institute of Microbial Technology, India.
Vice President, Legal Affairs
Ben Enerson is responsible for legal, compliance and intellectual property matters for Crestovo. Mr. Enerson has more than 12 years of experience in transactions, intellectual property and litigation. Prior to Crestovo, Mr. Enerson was corporate counsel at Moderna Therapeutics from 2015-2017, and Sunovion Pharmaceuticals from 2010-2015. He began his legal career as a litigation associate at Holland & Knight LLP and Fish & Richardson P.C.
Mr. Enerson holds a B.A. in chemistry from Vanderbilt University and a J.D. from Cornell Law School.
Vice President, Program Management and Operations
Sun Altbach is responsible for the overall integration and management of Crestovo’s portfolio of programs. Ms. Altbach has more than 18 years of experience in the healthcare and biopharmaceutical industry, spanning global medical affairs, program and portfolio management and operations. Prior to Crestovo, Ms. Altbach was senior director, global operations at OvaScience, based in the UK. Before OvaScience, Ms. Altbach served in senior roles across multiple business units at Shire, Genzyme and Biogen.
Ms. Altbach holds a B.A. in psychology from Smith College and an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management.
FOUNDER AND SCIENTIFIC ADVISOR
Thomas J. Borody, M.D.
Founder and Medical Director, Centre for Digestive Diseases in Australia
Dr. Borody is a world-renowned leader in clinical microbiota dating back to 1988 when he started performing what is now called Fecal Microbiota Transplantation (FMT). As a practicing clinician leading the Centre for Digestive Diseases in Sydney, Australia, he has overseen more than 12,000 FMTs, creating a wealth of proprietary clinical data and insights. In addition, Dr. Borody has established novel therapies in the gastrointestinal field, including areas such as inflammatory bowel disease, Clostridium difficile infection, parasite infestation, resistant helicobacter pylori via a bismuth-based ‘Triple Therapy’. His knowledge and expertise are sought after by patients around the world, and he is a reviewer for leading medical journals including the Clinical Journal of Gastroenterology, the Medical Journal of Australia, the American Journal of Gastroenterology, and Digestive Diseases and Sciences.
Alexander Khoruts, M.D.
Medical Director, Microbiota Therapeutics Program and Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition at the University of Minnesota
Dr. Khoruts is the Medical Director of the University of Minnesota Microbiota Therapeutics Program, and has been one of the leaders in the field of fecal microbiota transplantation (FMT). Some of Dr. Khoruts’ accomplishments include being the first to demonstrate that FMT results into engraftment of donor gut microbiota into recipients suffering from multiple recurrent Clostridium difficile infections (CDI), publication of a standardized protocol of fecal microbiota preparation and cryopreservation, and securing an IND from the FDA for a clinical trial with FMT. The Microbiota Therapeutics Program is continuing to deliver care for patients suffering from CDI. Dr. Khoruts’ current research includes development of next-generation microbiota therapeutics, understanding the mechanisms of FMT in treatment of CDI and applications of FMT in conditions other than CDI.
Dr. Khoruts trained in gastroenterology and basic immunology at the University of Minnesota. In addition to completing his fellowship in gastroenterology, he also trained in basic immunology as a Howard Hughes Physician Fellow under the mentorship of Dr. Marc Jenkins. His early research career was focused on the basic biology of regulatory T cells and lymphocyte homeostasis. His current primary clinical focus continues to be patients with CDI.
Michael Sadowsky, Ph.D.
Director, Biotechnology Institute and Professor of Microbiology at the University of Minnesota
Dr. Sadowsky, a fellow in the prestigious American Academy of Microbiology, is internationally known and respected for his research on the relationship between microbial ecology, genomics, and host-microbe interactions. He has published more than 310 original, peer-reviewed articles, and his work is widely cited by researchers in several scientific disciplines. He has been using metagenomic analyses of the human gastrointestinal (GI) tract, performed using new DNA sequencing and computational methods, to provide valuable insights into host-microbe interactions, the microbial ecology of this complex ecosystem and practical knowledge about how human GI tract microorganisms are related to human health. Over the last nine years, he has been studying the curative effects of fecal microbiota transplantation (FMT) on Clostridium difficile infection (CDI), and he was instrumental in developing new FMT technologies to treat CDI. More recently, he and his colleagues have developed the use of freeze-dried encapsulated fecal microbiota to treat CDI, helping bring this technology to mainstream medicine.
Crestovo has multiple partnerships with leading academic groups and investigators, and we are open to collaborating with others who share our interest in delivering novel patient solutions through the microbiome. If you would like more information about partnering with Crestovo, please email us at firstname.lastname@example.org.